Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a research note released on Wednesday,Benzinga reports. The firm currently has a $12.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $14.00.

Several other equities analysts have also issued reports on SAGE. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research report on Thursday, November 21st. TD Cowen cut their price objective on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, November 21st. Oppenheimer dropped their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 30th. Scotiabank dropped their price target on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, October 30th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.65.

Sage Therapeutics Stock Down 0.4 %

NASDAQ:SAGE opened at $7.16 on Wednesday. The business’s 50-day moving average price is $6.34 and its two-hundred day moving average price is $6.93. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $27.39. The stock has a market cap of $437.98 million, a P/E ratio of -1.28 and a beta of 0.94.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. On average, equities research analysts expect that Sage Therapeutics will post -6.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

Hedge funds have recently made changes to their positions in the business. Picton Mahoney Asset Management boosted its stake in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,581 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Sage Therapeutics in the fourth quarter worth about $49,000. Ieq Capital LLC bought a new position in shares of Sage Therapeutics in the fourth quarter worth about $57,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Sage Therapeutics by 66.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 4,672 shares during the period. Finally, Creative Planning bought a new position in shares of Sage Therapeutics in the third quarter worth about $88,000. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.